Switch theme
Sign up to access all valuation multiples
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
2014
41
LTM Revenue $62.3M
LTM EBITDA $3.9M
$190M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Journey Medical has a last 12-month revenue (LTM) of $62.3M and a last 12-month EBITDA of $3.9M.
In the most recent fiscal year, Journey Medical achieved revenue of $56.1M and an EBITDA of -$8.4M.
Journey Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Journey Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $62.3M | XXX | $56.1M | XXX | XXX | XXX |
| Gross Profit | $37.1M | XXX | $35.3M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $3.9M | XXX | -$8.4M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -15% | XXX | XXX | XXX |
| EBIT | -$7.8M | XXX | -$18.2M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -32% | XXX | XXX | XXX |
| Net Profit | -$10.4M | XXX | -$14.7M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Journey Medical's stock price is $8.
Journey Medical has current market cap of $186M, and EV of $190M.
See Journey Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $190M | $186M | XXX | XXX | XXX | XXX | $-0.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Journey Medical has market cap of $186M and EV of $190M.
Journey Medical's trades at 3.4x EV/Revenue multiple, and -22.7x EV/EBITDA.
Equity research analysts estimate Journey Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Journey Medical has a P/E ratio of -18.0x.
See valuation multiples for Journey Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $186M | XXX | $186M | XXX | XXX | XXX |
| EV (current) | $190M | XXX | $190M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 48.4x | XXX | -22.7x | XXX | XXX | XXX |
| EV/EBIT | -24.4x | XXX | -10.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -18.0x | XXX | -12.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJourney Medical's last 12 month revenue growth is 39%
Journey Medical's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.3M for the same period.
Journey Medical's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Journey Medical's rule of X is 103% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Journey Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -15% | XXX | XXX | XXX |
| EBITDA Growth | 422% | XXX | 109% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 103% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 95% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Journey Medical acquired XXX companies to date.
Last acquisition by Journey Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Journey Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Journey Medical founded? | Journey Medical was founded in 2014. |
| Where is Journey Medical headquartered? | Journey Medical is headquartered in United States of America. |
| How many employees does Journey Medical have? | As of today, Journey Medical has 41 employees. |
| Who is the CEO of Journey Medical? | Journey Medical's CEO is Mr. Claude Maraoui. |
| Is Journey Medical publicy listed? | Yes, Journey Medical is a public company listed on NAS. |
| What is the stock symbol of Journey Medical? | Journey Medical trades under DERM ticker. |
| When did Journey Medical go public? | Journey Medical went public in 2021. |
| Who are competitors of Journey Medical? | Similar companies to Journey Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Journey Medical? | Journey Medical's current market cap is $186M |
| What is the current revenue of Journey Medical? | Journey Medical's last 12 months revenue is $62.3M. |
| What is the current revenue growth of Journey Medical? | Journey Medical revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of Journey Medical? | Current revenue multiple of Journey Medical is 3.1x. |
| Is Journey Medical profitable? | Yes, Journey Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Journey Medical? | Journey Medical's last 12 months EBITDA is $3.9M. |
| What is Journey Medical's EBITDA margin? | Journey Medical's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Journey Medical? | Current EBITDA multiple of Journey Medical is 48.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
